

CARDIOLOGY
2023

THE SUCCESSFUL AND DRAMATIC REDUCTION IN INTERSTAGE MORTALITY

How Did We Do This?



Sunday, February 26, 2023

CARDIOLOGY
2023

THE SUCCESSFUL AND DRAMATIC REDUCTION IN INTERSTAGE MORTALITY

How Did We Do This?

...And What Comes Next?




Sunday, February 26, 2023

OVERVIEW

- Review of interstage period & mortality
- Background on home monitoring
- Future directions

INTERSTAGE PHYSIOLOGY



THE INTRODUCTION OF HOME MONITORING

Surgery for Congenital Heart Disease

Congenital Heart Disease

Rudd et al

Improving interstage survival after Norwood operation: Outcomes from 10 years of home monitoring

Nancy A. Rudd, MS, CPNP,^{a,d} Michele A. Frommelt, MD,^{a,d} James S. Tweddell, MD,^{c,d}
David A. Hehir, MD,^{a,b,d} Kathleen A. Mussatto, PhD,^d Katherine D. Frontier, MS, CCC-SLP,^d

VS 2014

Norwood
S1P

Interstage
Period

S2P

P. C. Frommelt, MD^{b,c}
N. A. Rudd, MSN^c
M. M. Steltzer, MSN^c
S. M. Bevandic, BSN^c
S. J. Frisbee, MS^f
R. D. B. Jaquiss, MD^g
S. B. Litwin, MD^g
J. S. Tweddell, MD^g

JTCVS 2003

WHAT DOES HOME MONITORING ENTAIL?

Prior to
Discharge

- Discharge check-lists
- Parental education

For Home

Standard
Follow-up
Care

Table 1. Common Interstage Home Monitoring Red Flags^{4, 10, 14, 15} (Table view)

Red Flags
Oxygen saturation $\leq 75\%$ ^a
Failure to gain 20 g (=0.02 kg) in 3 d
Weight loss ≥ 30 g (=0.03 kg)
Enteral intake < 100 mL/kg per d
Cyanosis, pallor
Irritable, fussy
Diarrhea or vomiting
Increased sweating
Respiratory changes (tachypnea, distress)
Temp $> 100.4^{\circ}\text{F}$

^a Unanticipated increase in oxygen saturation from baseline (eg $\geq 90\%$ in infant with Norwood physiology) should be considered a red flag.

THE IMPACT OF HMPS: REDUCED MORTALITY

Table 1. Studies reporting interstage mortality and impact of HMP

First author and study	Period	Population (n)	Results/Comments
Mahle 2000 (CHOP)	1984–1999	840	Interstage death = 13.9% (no HMP)
Ghanayem 2003 (CHW)	1996–2001	87	Pre-HMP = 15.8%; HMP = 0%
Fenton 2003 (PITT)	1991–2000	146	Interstage death = 14% (no HMP)
Hehir 2009 (CHOP)	1998–2005	368	Pre-HMP = 13%, HMP = 5.4%
Furck 2010 (Kiel)	1996–2007	157	Pre-HMP = 15.8%; HMP = 0%
Hansen 2011 (Kiel)	1996–2009	187	Pre-HMP = 12.4%; HMP = 0%
Debrolet 2011 (Miami)	2006–2010	59	Control = 6%; HMP = 0%
Petit 2011 (TCH)	2007–2010	230	Pre-HMP = 17%; HMP = 0%
Husain 2012 (NCH)	2006–2011	51	No HMP
Ghanayem 2012 (SVR)	2005–2008	42	No HMP

CHOP, Children's Hospital of Philadelphia; CHW, Children's Hospital of Wisconsin; Kiel, Germany; Miami, Miami Children's Hospital and Arnold Palmer Children's Hospital; PITT, Children's Hospital of Pittsburgh; SVR, Single Ventricle Reconstruction Trial.

Hehir DA, Ghanayem NS. Single-ventricle infant home monitoring programs: outcomes and impact on interstage mortality.

Journal of the American Heart Association
Volume 8, Issue 10, 21 May 2019
<https://doi.org/10.1161/JAHA.118.010783>

Association of a Home Monitoring Program with Interstage and Stage 2 Outcomes

Monique M. Gardner, MD^{1,2}; Laura Mercer-Rosa, MD¹; Michael P. DiLorenzo, MD, MSCE⁴; Katherine E. Bates, MD³; Shobha S. Natarajan, MD²; Anita Szwast, MD²; Stephanie L. Mascio, MD⁷; Desiree Fleck, PhD, CRNP⁶; Deborah L. Torowicz, MD²; Jonathan J. Rome, MD²; Chitra Ravishankar, MD²

No interstage mortality in HLHS from 2016 to 2022



National Pediatric Cardiology
Quality Improvement Collaborative

**Cumulative interstage mortality
has decreased from 9.5% to 5.1%**

0%?

SHIFTING GEARS: NOT JUST SURVIVE, THRIVE





Texas Children's Hospital®

Improved interstage weight gain, allowing early stage 2 at an equivalent weight



Children's
Wisconsin

Interstage infants enrolled in an HMP experienced normal growth velocity



Despite being younger at stage 2, HMP cohort had higher WAZ



Aggregate growth failure reduced from **18.6% to 13.3%**

CARDIOLOGY
2023

THE DOWNSIDES OF HOME MONITORING?



**MORE
EMERGENCY
ROOM VISITS**



**MORE
REINTERVENTIONS**



**MORE
READMISSIONS**



**YOUNGER AGE
AT S2P**

**CARDIOLOGY
2023**

Edelson et al, 2018 Journal of American College of Cardiology
Hanke et al, 2016 Seminars in Thoracic and Cardiovascular Surgery
Gardner et al. 2019 Journal of American Heart Association

Buelow et al, 2018 Congenital Heart Disease
Meza et al, 2018 Annals of Thoracic Surgery


MORE DOWNSTREAM EFFECTS



ORIGINAL ARTICLE


Caregiver Anxiety Due to Interstage Feeding Concerns

Jamie Stewart RN, Robert Dempster PhD, Robin Allen RN, Holly Miller-Tate RN, Gabrielle Dickson RN, Samantha Fichtner RN, Alex J. Principe MBA, Rachel Fonseca BS, Lisa Nicholson PhD, Clifford L. Cua MD



Sick Kids Health. Nasogastric (NG) Tube: How to insert your child's NG tube.

CARDIOLOGY
2023




Rudd, et al. "Interstage Home Monitoring for Infants With Single Ventricle Heart Disease: Education and Management: A Scientific Statement From the American Heart Association." *Journal of the American Heart Association* 9.16 (2020): e014548.



IDENTIFYING OUTLIERS

CHOP Practice For In-Hospital Interstage



FUTURE DIRECTIONS FOR HOME MONITORING



- Deliver More **Equitable** Care
- Advance Care Through **Telemedicine**
- **Personalized** Care
- Interstage Care **2.0?**

DELIVERING MORE EQUITABLE CARE

Journal of the American Heart Association

Volume 7, Issue 3, 2 February 2018

<https://doi.org/10.1161/JAHA.117.007065>



ORIGINAL RESEARCH - CONGENITAL HEART DISEASE
CONGENITAL HEART DISEASE

Neighborhood Socioeconomic Status and Outcomes Following the Norwood Procedure: An Analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Data Set

Emily M. Bucholz, MD, PhD, MPH^{1,2}; Lynn A. Sleeper, ScD^{2,3}; Jane W. Newburger, MD, MPH^{*,2,3}




DELIVERING MORE EQUITABLE CARE



Rachel Shustak, MD MSCE

CARDIOLOGY
2023



LEVERAGING TECHNOLOGY



Pediatric Cardiology (2023) 44:196–203
<https://doi.org/10.1007/s00246-022-02993-y>


ORIGINAL PAPER

Initial Experience with Telemedicine for Interstage Monitoring in Infants with Palliated Congenital Heart Disease


Alyson Stagg^{1,2} · Therese M. Giglia^{1,2} · Monique M. Gardner^{1,2} · Bonnie F. Offit¹ · Kate M. Fuller¹ · Shobha S. Natarajan^{1,2} · David A. Hehir^{1,2} · Anita L. Szwasz^{1,2} · Jonathan J. Rome^{1,2} · Chitra Ravishankar^{1,2} · Benjamin L. Laskin^{1,2} · Tamar J. Preminger^{1,2}

Received: 16 May 2022 / Accepted: 17 August 2022 / Published online: 1 September 2022


© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022




PERSONALIZED HMP: NOVEL BIOMARKERS OF RISK




PERSONALIZED HMP: NOVEL BIOMARKERS OF RISK



PERSONALIZED HMP: NOVEL BIOMARKERS OF RISK



PERSONALIZED HMP: NOVEL BIOMARKERS OF RISK



THE [SECOND] INTERSTAGE PERIOD?

Carlo et al

Congenital Heart Disease

Interstage attrition between bidirectional
palliation in children with hypoplastic

*“Interstage attrition between
Fontan procedures occurs in a
population”*

Could home
monitoring
make a
difference?



The Journal of Thoracic and Cardiovascular
Surgery


Available online 22 October 2020

In Press, Journal Pre-proof



Attrition Between the Superior Cavo-Pulmonary
Connection and the Fontan Procedure in
Hypoplastic Left Heart Syndrome

*“In this study spanning more than 3 decades,
8.3% of children with HLHS failed to
undergo Fontan after SCPC.
Attrition rate has not decreased over 30 years.”*



Should we tailor our monitoring to the patient?



Uniform, standardized care?

SO, HOME MONITORING: HOW DID WE DO THIS AND WHAT COMES NEXT?



Alyson Stagg, CRNP

CARDIOLOGY
2023

